UCLA researchers in the Department of Chemistry & Biochemistry have developed a method for using in vitro reconstituted plant virus-derived vectors to package and deliver RNA genes for targeted delivery of vaccines, MRI contrast agents, and therapeutic proteins in RNA form.
The development of RNA-based drugs has been slow due to challenges in delivering RNA to target cells. Some of these involve safety concerns, since RNA drugs cannot be controlled after application. Also, bioavailability is a challenge due to the endogenous presence of RNases that will degrade RNA drugs. Current methods utilizing nanocarriers or liposomes have often resulted in inefficient targeting, as endosomal degradation can also occur. Therefore, RNA delivery requires efficient targeting to the proper cell and the ability to avoid degradation.
Researchers at UCLA have discovered that cowpea chlorotic mottle virus (CCMV) capsid proteins have the unique ability to spontaneously self-assemble around heterologous RNA molecules of widely varying length and sequence. RNA in these nucleocapsids are protected from degradation and are able to release the RNA in the cytoplasm of target mammalian cells. Additionally, a ligand that binds to target cells can be conjugated to the capsid to facilitate cytoplasmic entry of RNA-containing nucleocapsids.
|United States Of America||Issued Patent||10,221,399||03/05/2019||2014-111|
|United States Of America||Issued Patent||9,605,031||03/28/2017||2014-111|
RNA-drug delivery, RNA vaccine delivery, targeted drug therapy, RNA-containing MRI contrast agents, in-vitro reconstituted plant virus capsids, nucleocapsids for drug delivery, delivering RNA to mammalian cells